The role of olive oil in disease prevention: a focus on the recent epidemiological evidence from cohort studies and dietary intervention trials

Genevieve Buckland* and Carlos A. Gonzalez

Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO-IDIBELL), Avda Gran Via 199-203, Barcelona 08907, Spain

(Submitted 17 June 2014 – Final revision received 28 October 2014 – Accepted 31 October 2014)

Abstract

Consumption of olive oil within the Mediterranean diet has been long known to have many health benefits. However, only over the last decade has epidemiological research confirmed its protective role against developing several chronic diseases. The objective of this review was to give an overview of the state of art epidemiological evidence concerning the relationship between olive oil and key public health outcomes including mortality, CVD, diabetes, metabolic syndrome (MetS), obesity, and cancer, with a particular focus on recent results from cohort studies and dietary intervention trials. Recent epidemiological research has shown that regular consumption of olive oil is associated with increased longevity. This benefit is partly due to the olive oil’s unequivocal cardio-protective role. There is converging evidence on the benefits of olive oil for preventing several CVD risk factors, including diabetes, MetS and obesity. Olive oil is also implicated in preventing certain cancers, with the most promising findings for breast and digestive tract cancers, although the data are still not entirely consistent and mainly from case–control studies. These health benefits are supported by strong mechanistic evidence from experimental studies, demonstrating that specific components of olive oil have antihypertensive, antithrombotic, antioxidant, antiinflammatory and anticarcinogenic action. Despite the accumulating epidemiological research, there is still a lack of consistent results from high-quality studies for many health outcomes (i.e. certain cancers and metabolism-related disorders). Further research is mandatory, above all from prospective studies and randomised dietary intervention trials when feasible, to confirm some of the still potential health benefits.

Key words: Olive oil; Disease prevention; Health; Epidemiological evidence

For centuries, olive oil has been recognised for its nutritional properties and has been associated with human health benefits, being considered by ancient Greeks as an ‘elixir of youth and health’(1,2). Olive oil is an integral feature of the traditional Mediterranean diet, being the main source of dietary fat and contributing to a third to two-thirds of total vegetable fat(3), where total fat can provide 25–35% of total energy(4,5). In fact, the moderately high-fat content of the Mediterranean diet is what distinguishes it from other healthy dietary models(4–6).

Regular consumption of olive oil, within the context of the Mediterranean diet, has been related to a reduced risk of several chronic diseases, above all CVD(2,7–9). There is abundant experimental evidence outlining the biological mechanisms by which components of olive oil could exert these health benefits(2,7,10–12). However, this experimental research needs to be supported by epidemiological studies set in populations characterised by regular long-term consumption of olive oil. Along these lines, epidemiological research into the relationship between olive oil and overall

Abbreviations: EPIC, European Prospective Investigation into Cancer and Nutrition; MetS, metabolic syndrome; PREDIMED, Prevención con Dieta Mediterránea; RCT, randomised controlled trial.

* Corresponding author: G. Buckland, fax +34 93 260 7787, email gbuckland@iconcologia.net

© The Authors 2015

doi:10.1017/S0007114514003936


Sapienza di Roma which are both non-paid, honorary positions. Goretti Guasch is the Executive Director and Member of the Executive Committee of the World Forum for Nutrition Research and Dissemination of the International Nut and Dried Fruit Council. Angel Gil is President of the Fundación Iberoamericana de Nutrición, which is a non-paid honorary position. Lluís Serra-Majem is the President of the Scientific Committee of the Mediterranean Diet Foundation and Scientific Director of the CIISCAM (Centro Interuniversitario di Ricerca sulle Culture Alimentari Mediterranee), Universita La Sapienza di Roma which are both non-paid, honorary positions. Goretti Guasch is the Executive Director and Member of the Executive Committee of the International Nut and Dried Fruit Council, which is a paid position. Mónica Bulló declares no conflict of interest.

Publications of these papers was supported by unrestricted educational grants from Federación Española de Sociedades de Nutrición, Alimentación y Dietética (FESNAD), International Nut and Dried Fruit Council (INC), International Union of Nutritional Sciences (IUNS), Fundación Iberoamericana de Nutrición (FINUT), Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBERobn) and Centro Interuniversitario di Ricerca sulle Culture Alimentari Mediterranee (Ciscam). The papers included in this supplement were invited by the Guest Editors and have undergone the standard journal formal review process. They may be cited. The Guest Editors declare that Salas-Salvadó is a nonpaid member of the World Forum for Nutrition Research and Dissemination of the International Nut and Dried Fruit Council. Angel Gil is President of the Fundación Iberoamericana de Nutrición, which is a non-paid honorary position. Lluís Serra-Majem is the President of the Scientific Committee of the Mediterranean Diet Foundation and Scientific Director of the CIISCAM (Centro Interuniversitario di Ricerca sulle Culture Alimentari Mediterranee), Universita La Sapienza di Roma which are both non-paid, honorary positions. Goretti Guasch is the Executive Director and Member of the Executive Committee of the International Nut and Dried Fruit Council, which is a paid position. Mónica Bulló declares no conflict of interest.
mortality, CVD, metabolic diseases, cancer and other chronic diseases has been accumulating over the last decade. Despite this, evidence on the role of olive oil in the primary prevention of these end points has been very limited until recently. In addition, much of the evidence has come from case–control studies, especially with respect to cancer(13,14).

Recently published results from the randomised controlled trials (RCT) such as the ‘Prevención con Dieta Mediterránea’ (PREDIMED)(15) and cohort studies such as the European Prospective Investigation into Cancer and Nutrition (EPIC)(16–18) have provided more solid epidemiological evidence on the health benefits of olive oil. Therefore, in the present study, the role of olive oil in disease prevention is reviewed with a particular focus on the recent epidemiological evidence from RCT and cohort studies, published until April 2014. This information is particularity relevant for nutritional researchers and the scientific community, whose conclusions about diet–health relationships need to be based on the results from high-quality epidemiological studies. RCT are able to overcome the many study limitations of observational studies, while well-designed cohort studies are also advantageous over case–control studies, which can be prone to recall and selection bias. Reviews of this nature are needed to update the present understanding of the potential role of olive oil in disease prevention.

**Mortality**

The first indirect evidence indicating that consuming olive oil, within the Mediterranean diet, might increase longevity originated from the Seven Countries Study(19), followed by the MONICA study(20), which observed lower CHD incidence and mortality rates in Mediterranean countries compared with the USA or other European regions. These health benefits were attributed to their Mediterranean dietary pattern, which includes regular olive oil consumption. Since then, a meta-analysis of nine cohort studies found that there was a significant 8% decreased risk of dying related to each 2-unit increase in a Mediterranean diet score(21).

In the EPIC-Spain cohort, there was a significant 21% reduction in death associated with a high υ: low relative Mediterranean diet score(22). In the EPIC-Italy cohort(23), the upper quartile of a dietary pattern including olive oil and salad significantly reduced mortality by 50% (P_trend = 0.008) in the elderly.

Although olive oil is believed to play a key role in these health benefits(23,24,25), there is relatively little direct epidemiological evidence on the individual effects of olive oil on overall mortality. The EPIC-Greece cohort study(26) followed-up initially healthy adults for a median of 44 months and reported a negative but non-significant 4% reduction in overall mortality for each 20 g d oil. By contrast, an Italian clinical study (GISSI-Prevenzione trial), which was analysed as a cohort study, reported that regular

---

**Fig. 1.** The association between olive oil consumption (quartiles (Q) and per 10 g/d) and (a) overall mortality and cause-specific mortality (b) CVD mortality, (c) cancer mortality and (d) other causes of mortality) in the European Prospective Investigation into Cancer and Nutrition Spanish cohort study.
olive oil consumption (compared with none or infrequent consumption) significantly reduced mortality risk by 24% ($P_{trend} = 0.01$) in men and women with previous myocardial infarction (27). The results from the GISSI-Prevenzione trial cannot be extrapolated to a healthy adult population though. However, recent results from the EPIC-Spain cohort have provided some of the clearest evidence to date that olive oil consumption, independent from the Mediterranean dietary pattern, is related to a reduction in overall mortality (22). Olive oil consumption was negatively related to overall and CVD mortality after following 40,622 initially healthy volunteers from Spain for 13.4 years (identifying 1915 deaths during this period). Compared with non-consumers (15% of the sample), the top quartile of olive oil consumption (participants consuming over 24.9 g/8373.6 kJ (2000 kcal) per d) was associated with a 26 (95% CI 13, 36) % decrease in overall mortality, and an impressive 44 (95% CI 21, 60) % decrease in CVD mortality (Fig. 1(a) and (b)), after multivariate adjustment including components of the Mediterranean diet. No significant association was observed between olive oil and cancer mortality, but there was a strong inverse association for other causes of death that included respiratory, digestive and nervous system diseases (Fig. 1(c) and (d)). No differences were found while separately assessing the effect of virgin and ordinary olive oil on overall mortality. In summary, although the Mediterranean dietary pattern has been long recognised for increasing longevity, only recent epidemiological evidence (from cohort studies) has shown that high intakes of olive oil, independent from the Mediterranean dietary pattern, is related to reduced risk of dying by approximately 25%.

**CVD**

Since the renowned Seven Countries Study by Keys et al. (19,28), numerous subsequent epidemiological studies have now quite conclusively demonstrated that a Mediterranean diet including a regular intake of olive oil can prevent CVD (9,21,29). A meta-analysis of eight prospective cohort studies (21) reported that a two-point increment in a Mediterranean diet score was associated with a significant 10 (95% CI 7, 13) % lower risk of CVD incidence or mortality (studies with both end points were included in the meta-analysis). It has been generally accepted that olive oil (particularly virgin and extra virgin) plays a key role in the Mediterranean diet’s cardio-protective effect, attributed to its beneficial effects on many CVD risk factors, including blood pressure, lipid profiles, endothelial function, inflammation and thrombosis, and factors related to the metabolic syndrome (MetS) (7).

Despite considerable evidence on the biological mechanisms involved (7,20,31), only up until recently have epidemiological studies provided direct evidence on the relationship between olive oil consumption and primary prevention of CVD (9,32). In 2012, the EPIC-Spain cohort study presented results on the association between olive oil intake and incident CHD from prospective data on 40,142 participants from Spain followed up for 10.4 years (18) (with 587 CHD events registered). A negative association between olive oil intake and CHD was observed (HR 0.78 (95% CI 0.59, 1.03) for the top quartile intake (≥28.9 g/d)), and there was a greater decreased risk of CHD events for consuming virgin compared with ordinary olive oil (HR 0.86 (95% CI 0.72, 1.01) and HR

![Fig. 2. The association between olive oil and CHD in population subgroups in the European Prospective Investigation into Cancer and Nutrition Spanish cohort study.](https://www.cambridge.org/core/terms).
Olive oil and disease prevention

Diabetes, metabolic syndrome and obesity

It is also becoming clear that consumption of olive oil within the Mediterranean diet can influence health outcomes such as type 2 diabetes mellitus, MetS and obesity, all of which are CVD risk factors. The EPIC-Interact study, including 11 994 incident type 2 diabetes mellitus cases and a stratified sub-cohort of 15 798 participants, found that participants with a high compared with a low relative Mediterranean diet score were 12 (95% CI 3, 21)% less likely to develop diabetes. In further analyses, they found that olive oil was one of the key components involved in this protective effect. The SUN cohort also found that adherence to the Mediterranean diet was inversely related to incident diabetes, and although no association was found with olive oil, the small number of diabetes cases (n = 42) may have limited the study power. The clearest evidence that olive oil may prevent diabetes comes from PREDIMED study, including 3541 patients at high CVD risk followed up for 4-1 years. The participants following a Mediterranean diet rich in extra-virgin olive oil had a 40 (95% CI 15, 57)% reduced incidence of type 2 diabetes mellitus than the control group. The PREDIMED also provided results showing that an olive oil-rich Mediterranean diet can improve glucose metabolism and reduce body weight, factors intrinsically related to the onset of diabetes. Finally, there is scientific evidence that MUFA diets, especially based on olive oil, are an alternative approach to low-fat diets for effective nutritional treatment of diabetes.

There is also increasing evidence suggesting that an olive oil-rich Mediterranean diet could help prevent diseases related to chronic inflammation and therefore be a useful tool in the lifestyle management of the MetS. Several epidemiological studies have found that a Mediterranean diet including olive oil is associated with reduced risk of the individual components of MetS, and a few observational studies (i.e. ATTICA cross-sectional study and the SUN cohort) have also found that it is related to the entire MetS. The PREDIMED olive oil-rich Mediterranean diet improved several aspects of MetS, including reductions in blood pressure and insulin resistance and improvements in dietary lipid profiles. Although after 1 year of the intervention, there was no significant difference in the reversion of MetS (61-4% at baseline) between the olive oil-enriched group and the control group. However, the olive oil group showed significant increases in plasma oleic acid, which was beneficially associated with the incidence, reversion and prevalence of MetS. The clinical dietary intervention trial by Esposito et al. found that following a Mediterranean diet including olive oil did reduce prevalence of MetS and its CVD related risk factors.

Finally, observational and dietary intervention trials consistently show that a Mediterranean diet rich in olive oil does not contribute to obesity and according to a systematic review published in 2008 including twenty-one epidemiological studies may actually help curb it. Since then, the EPIC-PANACEA cohort study showed that individuals with high adherence to a Mediterranean diet (including olive oil) were 10% significantly less likely to develop overweight or obesity. The PREDIMED study has also shown that an olive oil-rich diet was effective in the prevention of weight gain. Despite these supportive results, there is little data on the role of olive oil, independent of the Mediterranean diet, in preventing or managing obesity. However, the relationship is plausible considering that the habitual use of olive oil in salad and vegetable dishes within the Mediterranean diet enhances palatability and consequentially consumption of these low-density foods. In addition, MUFA have been found to improve glucose metabolism and increase postprandial fat oxidation and diet-induced thermogenesis over diets higher in saturated fats.

In summary, consuming olive oil within the context of a Mediterranean diet may also serve to prevent diabetes, obesity and diseases related to chronic inflammation such as the MetS. However, research in this area is relatively new and more studies need to clarify the specific role of olive oil independent of the Mediterranean diet on these disease outcomes.
Cancer

There is mounting epidemiological research suggesting that olive oil might reduce the risk of certain cancers, and two recent systematic reviews published in 2011 have summarised the epidemiological research in this area\(^\text{13,14}^\). The review by Psaltopoulou et al.\(^\text{13}^\) carried out a meta-analysis of nineteen case–control studies including 13800 patients and 23540 controls, with additional meta-analyses by cancer sites (breast, digestive and other). Participants in the highest compared with the lowest category of olive oil consumption were 34 (95% CI 25, 41)\% less likely to have any type of cancer. There was a significant inverse association irrespective of study setting (Mediterranean or non-Mediterranean). The review by Pelucchi et al.\(^\text{14}^\) included twenty-five epidemiological studies (twenty-four case–control studies and one cohort study).

Breast cancer

The systematic review by Pelucchi et al.\(^\text{14}^\) included six case–control studies on breast cancer, which reported inverse associations between olive oil and breast cancer but three were not significant. The pooled results of five of these six case–control studies (one was excluded due to lack of information on CI) resulted in a significant 38 (95% CI 22, 56)\% reduction in risk for a high olive oil intake. The only cohort study in this review, EPIC-Greece\(^\text{53}^\) based on 14807 women (240 incident breast cancer cases) with a 10-year follow-up, reported a negative but non-significant association: RR 0.93 (95% CI 0.80, 1.08) overall and RR 0.85 (95% CI 0.69, 1.06) for postmenopausal women for each 21 g/d of olive oil increment. A meta-analysis of five case–control studies by Psaltopoulou et al.\(^\text{13}^\) (including one different study from the meta-analysis by Pelucchi et al.\(^\text{14}^\)) reported a significant 37 (95% CI 11, 54)\% lower likelihood of having breast cancer for a high compared with a low olive oil intake.

Since these reviews were published, a prospective study in the EPIC-MED cohort\(^\text{17}^\) has researched the effect of olive oil on breast cancer risk in women from Spain, Italy and Greece. This is the largest cohort study to date, including 62284 postmenopausal women followed up for 9 years (including 1256 incident breast cancers) and a mean olive oil intake of 24.7 g/d. Although no association was found between olive oil intake and overall breast cancer, in analyses stratified by hormone receptor status, there was a more pronounced, albeit still non-significant, reduction in breast cancer risk in women with oestrogen- and progesterone receptor-negative tumours (HR 0.77 (95% CI 0.84, 1.26)).

Digestive system cancers

The epidemiological research on olive oil and digestive system cancers is also based on case–control studies and largely drawn from Italian populations, with few studies on each separate site (stomach, colorectum and pancreas)\(^\text{13,14}^\). Although there was a significant negative association for colorectal cancer and olive oil intake in a large Italian case–control study including 1953 cases and 4154 controls\(^\text{52}^\), the majority of the other studies have observed inverse boarderline or non-significant associations. A meta-analysis of eight case–control studies by Psaltopoulou et al.\(^\text{13}^\) reported a significant 30 (95% CI 19, 39)\% lower likelihood of having digestive system cancers (colorectal, oral cavity, pharynx and oesophagus, and pancreatic) for a high compared with low olive oil intake.

Other cancer sites

There are a number of case–control studies conducted in different European countries that have researched the link between upper aero-digestive tract cancers (including oral cavity, larynx, pharynx, nasopharynx and oesophagus) and olive oil\(^\text{13,14}^\). Although there are few studies on each site, all the studies reported significant inverse associations, with risk reductions ranging from 22 to 74\% for the highest v. the lowest consumption. The evidence concerning other cancer sites is scarce, but includes case–control studies on lung, prostate, bladder and thyroid cancers with generally insignificant results (except for bladder)\(^\text{17,51}^\). Therefore, it is difficult to draw any clear conclusions from this research.

In summary, there is still a lack of definite evidence on the role of olive oil in preventing specific cancers, since studies are limited in number for many cancer sites, are often sub-optimal quality and the data are not entirely consistent. However, the most promising findings suggest that consuming olive oil may reduce risk of developing breast cancer and digestive system cancers.

Biological mechanisms

Olive oil’s health benefits have been traditionally attributed to its high MUFA content, principally oleic acid that can provide 55–83\% of fatty acid content\(^\text{22}^\). However, olive oil is a functional food that in addition to its high oleic acid content contains many minor but highly bioactive compounds\(^\text{38}^\), which while only present in 1–2\% of oil weight include over 250 chemical compounds\(^\text{9}^\) (including tocopherols, squalene, fatty acids, triterpenic acids, plant sterols, polar pigments and hydrophilic compounds, principally polyphenols such as oleuropein and its metabolites hydroxytyrosol and tyrosol, which make up approximately 80\% of olive oil’s phenolic content)\(^\text{7}^\). The phenolic compounds are predominantly present in virgin and extra-virgin olive oil when the olive juice is obtained purely by mechanically pressing the olives (many compounds, particularly polyphenols, are lost in the refining process used to produce ordinary or refined olive oil\(^\text{22,53}^\)).

While the specific mechanisms involved are not fully understood, nowadays it is widely accepted that they are numerous and complex and that the specific biological pathways may vary depending on the disease. In terms of cancer prevention, experimental in vitro and human in vitro studies have found that olive oil’s components has several chemopreventive effects related to the initiation, promotion and progression of carcinogenesis\(^\text{57}^\), with biological mechanisms including squalene, oleanolic acid and polyphenol’s antioxidant...
action, which can reduce cellular oxidative stress and DNA damage from reactive oxygen metabolites \(^{54}\). Polyphenols, in particular hydroxytyrosol and tyrosol, have been shown to have potent anti-inflammatory effects and may also influence cell proliferation, cell cycle progression, apoptosis and arachidonic acid metabolism in cancer cells \(^{31,55,56}\). In addition, specific compounds have been shown to have the potential to influence gene expression, such as oleic acid's ability to alter expression of certain oncogenes (Her-2/neu) associated with aggressive tumours in breast cancer \(^{57,58}\).

The mechanistic pathways that support olive oil's cardioprotective role are probably the clearest although, with results from many experimental studies showing that olive oil consumption improves a number of important CHD risk factors \(^{2,7,59,60}\). In PREDIMED, extra-virgin olive oil improved blood pressure, glycaemic control in diabetics, endothelial function, oxidative stress and lipid profiles (decreasing TAG, increasing HDL and lowering total and LDL-cholesterol) and reduced concentrations of inflammatory markers such as C-reactive protein and IL-6 \(^{61,62}\). The EUROLIVE study (Effect of Olive Oil Consumption in European Populations), a large crossover multi-centre clinical trial, found that in vitro consumption of olive oil with different phenolic concentrations increased HDL, decreased total cholesterol and oxidative stress markers and decreased TAG levels in a dose-dependent manner \(^{2,59}\). Olive oil's polyphenols have also been shown to inhibit LDL oxidation, platelet aggregation, apoprotein derivatisation \(^{2,8,63,64}\). The use of olive oil may also help prevent obesity or curb weight gain because it increases consumption of salads and vegetable and legume dishes that are high in fibre and low in energy density resulting in greater satiation and sateity \(^{36}\).

**Research limitations**

Most of the epidemiological evidence on olive oil and health, apart from data on olive oil's role in preventing CVD and its risk factors, has come from observational studies that have inherent study limitations. For instance, olive oil consumption could be an indication of a healthier diet, in particular vegetable intake, as in Mediterranean countries it is used for dressing salads and cooking vegetable dishes. Olive oil might also be related to other healthy lifestyle behaviours, thus inverse associations in observational studies could be partly due to these related factors, as although many of the studies adjust for dietary and lifestyle factors, some residual confounding may remain and could lead to an overestimation of the health benefits of consuming olive oil. In addition, many studies explore the relationship between a Mediterranean diet rich in olive oil and health outcomes, but olive oil's exact contribution within the dietary pattern is not always clear. Many observational studies also lack information on the type of olive oil intake and are therefore unable to explore the possible added benefit of consuming virgin and extra-virgin olive oil, rich in polyphenols, compared with ordinary olive oil. Finally, the evidence on cancer is mainly based on case–control designs, which are affected by recall and selection bias and therefore are not the best design to assess diet–disease relationships. Further RCT are also needed because results from observational studies limit the interpretation of findings as directly causal.

**Conclusions and future research**

The accumulating epidemiological research indicates that consuming olive oil clearly protects against CVD and its risk factors and may also serve to prevent diabetes, obesity and diseases related to chronic inflammation such as the MetS. Olive oil may also have a protective role against certain cancers (in particular breast and digestive tract cancers) but since robust data are still lacking more and better quality epidemiological studies are needed, in particular well-designed cohort studies and if feasible RCT. Olive oil's role in preventing diabetes and MetS merits further research too. In addition, other possible health benefits of olive oil should also be explored, such as its potential role in preventing or delaying cognitive decline and dementia \(^{65,66}\). Future research is also needed to clarify whether olive oil's potential beneficial effect is due to the fact that it encourages the consumption of vegetables and is intrinsically linked to the Mediterranean diet or whether it is olive oil's bioactive components \(^{per se}\), and if these can be attributed to its MUFA content or other micro-components. Future studies should also differentiate between the health effects of consuming virgin or extra-virgin olive oil compared with ordinary olive oil. Identifying new biomarkers of olive oil intake would also be advantageous to overcome problems of measurement error in observational studies \(^{67,68}\), as accurately quantifying the amount of olive oil consumed is challenging since it is used in preparation of many cooked dishes and is added to salads and vegetables dishes. The most commonly used biomarkers are two metabolites, hydroxytyrosol and tyrosol, which can be measured in human plasma and urine with a good dose–response \(^{56}\). However, they have a short elimination half-life and hydroxytyrosol reaches the limit for quantification in plasma after approximately 8 h \(^{69}\), which is a constraint for many observational studies that often take morning fasting blood samples where these metabolites would not be detectable anymore.

In conclusion, research in this area shows that there are many health benefits from regularly consuming olive oil, particularly with regard to the primary prevention of CVD. However, more high-quality studies are necessary to obtain more conclusive and complete evidence regarding its role in preventing certain cancers, to clarify the specific role of olive oil consumption independent of the Mediterranean diet for metabolism-related disorders and obesity, and finally to research olive oil's possible beneficial influence on other health outcomes such as neurodegenerative disorders.

**Acknowledgements**

The present study was financially supported by The Spanish Ministry of Health (ISCIII RETICC RD06/0020/0091 and RD12/0036/0018) and the Catalan Institute of Oncology.
The authors’ contributions are as follows: G. B. carried out the literature review and wrote the manuscript; C. A. G. oversaw and revised the manuscript. The authors have no conflicts of interest.

References